

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claim in the application.

Listing of Claims:

Claims 1 – 28 (Cancelled)

Claim 29. (Currently amended) A potassium salt of losartan in crystal Form X characterized by a powder X-ray diffraction pattern with peaks at about 6.9, 13.8, 19.1, 20.6, 21.4, 24.0, 24.8, 25.9, 28.7 and 29.2 ± 0.2 degrees 2Θ ; and having a melting point of about 230 °C to about 237 °C.

19.1, 21.4, and 25.9

Claim 30. (Cancelled)

Claim 31. (Previously presented) A potassium salt of losartan in crystal Form X according to claim 29 characterized by a powder X-ray diffraction pattern essentially as depicted in Figure 31.

Claim 32. (Cancelled)

Claim 33. (Previously presented) A potassium salt of losartan in crystal Form X according to Claim 29 which is characterized by a purity of at least about 99% by weight.

Claim 34. (Previously presented) A potassium salt of losartan in crystal Form X according to Claim 29 which is characterized by a purity of at least about 99.80% by weight.

Claim 35. (Currently amended) A potassium salt of losartan in crystal Form X characterized by a powder X-ray diffraction pattern with peaks at about 6.9, 13.8, 19.1, 20.6, 21.4, 24.0, 24.8, 25.9, 28.7 and 29.2 ± 0.2 degrees 2Θ ; and having a melting point of about 230 °C to about 237 °C, wherein said potassium salt of losartan is in the form of particles and wherein at least about 50% of said particles have a diameter of about 5 μm to about 500 μm .

Claim 36. (Previously presented) A potassium salt of losartan in crystal Form X according to Claim 29 wherein at least about 50% of particles have a diameter less than about 100 μm .

Claim 37. (Previously presented) A pharmaceutical composition comprising the potassium salt of losartan in crystal Form X according to Claim 29 and a pharmaceutically acceptable excipient.

Claims 38 - 40. (Cancelled)

Claim 41. (Previously presented) A pharmaceutical composition in the form of a tablet comprising about 50mg of the potassium salt of losartan in crystal Form X according to Claim 29.

Claim 42. (Previously presented) A pharmaceutical composition in the form of a tablet comprising about 100mg of the potassium salt of losartan in crystal Form X according to Claim 29.

Claim 43. (Previously presented) A pharmaceutical composition in the form of a tablet comprising from about 50mg of the potassium salt of losartan in crystal Form X according to Claim 29 and about 12.50mg of hydrochlorothiazide.

Claims 44 – 50. (Cancelled)